Overview
Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA
Description
Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. After discontinue DMPA, patients have not used any method. Unwanted pregnancy are rising. The reason of abnormal uterine bleeding from DMPA aren't clearly understand. In present, no standard treatment to treat abnormal utrerine bleeding in DMPA users.This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA with minimal dose and minimal side effect
Eligibility
Inclusion Criteria:
- Abnormal uterine bleeding more than 7 days after first DMPA injection
- Provide inform consent with patient
- Can understand thai language
Exclusion Criteria:
- Have contraindication to use Tranexamic acid and estrogen such as hypertension, Stroke, MI, DM, Renal disease, Liver disease, CA breast etc.
- Have pathology in uterus from pelvic examination, pap smear and ultrasound
- Current pelvic infection
- Postpartum less than 6 months
- History deep vein thrombosis
- Breastfeeding